Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regeneron PharmaceuticalsLTS:0R2M +2.02%87 5-Year Yield-on-Cost % is 0.55 as of Jul. 27, 2026, which is 34% above its 10-year median of 0.41. GuruFocus rates LTS:0R2M with a GF Score™ of 87/100 and a GF Value™ of $902.72 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 150 Biotechnology companies, Regeneron Pharmaceuticals ranks worse than 80.67% on this metric.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Regeneron Pharmaceuticals 5-Year Yield-on-Cost % Related Terms
LTS:0R2M vs RVMD, ALNY, ONC: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Regeneron Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Regeneron Pharmaceuticals (LTS:0R2M) has a 5-Year Yield-on-Cost % of 0.55 as of Jul. 27, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Regeneron Pharmaceuticals and its competitors. This is 34% above median its historical median of 0.41. Over the past decade, Regeneron Pharmaceuticals' 5-Year Yield-on-Cost % has ranged from 0.15 to 0.59. According to the industry distribution chart, Regeneron Pharmaceuticals ranks #121 out of 150 companies in the Biotechnology industry, placing it in the top 80.7%.
Is Regeneron Pharmaceuticals' 5-Year Yield-on-Cost % too high?
Regeneron Pharmaceuticals' current 5-Year Yield-on-Cost % of 0.55 is 34% above median its 10-year median of 0.41. Over the past 10 years, this metric has ranged from a low of 0.15 to a high of 0.59. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.70. Regeneron Pharmaceuticals' value of 0.55 is 67.6% below this industry median. Based on the distribution chart, Regeneron Pharmaceuticals ranks #121 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Regeneron Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' 5-Year Yield-on-Cost % compare to RVMD and ALNY?
According to the Biotechnology industry distribution chart, Regeneron Pharmaceuticals ranks #121 out of 150 companies for 5-Year Yield-on-Cost %. This places Regeneron Pharmaceuticals in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.70. Regeneron Pharmaceuticals' value of 0.55 is 67.6% below this benchmark. Historically, Regeneron Pharmaceuticals' own 5-Year Yield-on-Cost % has ranged from 0.15 to 0.59 over the past decade. While the company's 10-year median is 0.41 vs. the industry median of 1.70, Regeneron Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.70, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regeneron Pharmaceuticals's current 5-Year Yield-on-Cost % of 0.55 is 67.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Regeneron Pharmaceuticals and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regeneron Pharmaceuticals's current 5-Year Yield-on-Cost % is 0.55, which is 34% above median its own 10-year median of 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (LTS:0R2M) is currently considered Modestly Undervalued. The stock's GF Value™ is $902.72, compared to a current price of $662.48 — trading 26.6% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.55, which is 34% above median its 10-year median of 0.41 and 67.6% below the Biotechnology industry median of 1.70. Regeneron Pharmaceuticals' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Regeneron Pharmaceuticals (LTS:0R2M), the current 5-Year Yield-on-Cost % is 0.55 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regeneron Pharmaceuticals (LTS:0R2M) Overvalued in 2026?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued.
The current stock price of $662.48 is trading 26.6% below its estimated GF Value™ of $902.72.
GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for LTS:0R2M:
5-Year Yield-on-Cost %: 0.55 (34% above median its 10-year median of 0.41)
GF Value™: $902.72 vs. price of $662.48 (26.6% below fair value)
Industry Position: 67.6% below the Biotechnology median (#121 of 150)
No single metric tells the full story. See the LTS:0R2M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
87GF Score
Get the complete analysis for LTS:0R2M
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R2M has been successfully added to your 
